top of page
Free_Sample_By_Wix.JPG
Sign up

Fatty liver- a silent epidemic

Writer: Saneka Chakravarty, MD, FACC
Saneka Chakravarty, MD, FACC
Nov 10, 2024
6 min read

Updated: Sep 10


Illustration of a liver with yellow and red cyst-like structures, set against a dark cellular background, highlighting liver disease.
Illustration depicting a liver affected by fatty liver disease, showcasing an accumulation of fat cells within the liver tissue.


Written by Dr Saneka Chakravarty, MD, FACC. Dr Chakravarty is a board-certified cardiovascular disease specialist focused on personalized preventive cardiovascular care.


Fatty liver disease, known in medical terms as hepatic steatosis, has become a pressing health issue worldwide. Often unnoticed until it reaches advanced stages, this “silent epidemic” affects millions of people without their awareness. With this post, we aim to illuminate the condition, exploring its causes, symptoms, and strategies for prevention and management. Most instances of Fatty liver stem from lifestyle choices. This escalating issue can lead to serious long-term complications like cirrhosis or liver failure, highlighting its importance.



Understanding Fatty Liver Disease


Fatty liver disease occurs when excess fat accumulates in the liver. It comes in two primary forms: alcoholic and non-alcoholic fatty liver disease (NAFLD)/metabolic dysfunction associated steatottic liver disease (MASLD). Alcoholic fatty liver is directly related to heavy alcohol use, while NAFLD/MASLD can develop in people who drink little to no alcohol.


The surge in fatty liver diagnoses is closely linked to unhealthy lifestyle choices, including poor diets, lack of exercise, and rising obesity rates. According to recent studies, approximately 25-30% of adults worldwide suffer from NAFLD(more common in males), underscoring the urgency of addressing lifestyle factors that contribute to this condition.


Who Is Affected?


Fatty liver disease spans across many demographics, affecting people of all ages and backgrounds. Research suggests that up to 80-100 million adults (25% of the population) in the United States alone may experience some form of NAFLD/MASLD.


Risk factors extend beyond obesity and type 2 diabetes; even individuals with a normal weight can develop fatty liver. Studies have found that about 10% of lean individuals can have NAFLD, and may be genetic, highlighting the importance of widespread awareness and testing for this condition. Certain ethnic groups may be at higher risk compared to others, and is related to increased fat deposits around vital organs instead of generalized pattern.


Symptoms of Fatty Liver Disease


Many individuals with fatty liver may not exhibit overt symptoms, making it challenging to detect early on. However, some signs that could indicate its presence include:


  • Fatigue

  • Discomfort in the upper right abdomen

  • Nausea


As the disease progresses and may lead to steatohepatitis (inflammation of the liver), symptoms can worsen and result in serious issues like cirrhosis or liver failure. Studies show that 20% of people with NAFLD/MASLD may have cirrhosis, emphasizing the need for awareness.


Risk Factors


Several risk factors can lead to the development of fatty liver disease:


  1. Obesity: Being overweight or obese increases the likelihood of developing NAFLD. Studies show that upto 90% of obese individuals may have fatty liver.


  2. Type 2 Diabetes: Individuals with insulin resistance are far more vulnerable, with up to 70% of diabetic patients developing fatty liver.


  3. High Cholesterol and Triglycerides: Poor lipid profiles can exacerbate liver fat accumulation.


  4. Medications: Certain medications, like corticosteroids and some cancer drugs, can induce fatty liver.


  5. Genetic Factors: If a family member has liver disease, your risk may be higher.


  6. Lifestyle Choices: Sedentary habits and diets high in sugar and unhealthy fats can greatly increase risk levels.


Understanding these risk factors allows individuals to take proactive measures towards prevention through lifestyle changes.


The Role of Diet and Lifestyle in Prevention


Proper diet and lifestyle choices are critical in managing and preventing fatty liver disease. Adopting the following habits can significantly reduce your risk:


  • Balanced Diet: Incorporating a variety of fruits, vegetables, whole grains, and healthy fats such as those from fish, nuts, and olive oil can minimize liver fat accumulation.


  • Regular Exercise: Engaging in at least 150 minutes of moderate aerobic activity each week can help maintain a healthy weight and improve insulin sensitivity.


  • Limit Sugar Intake: Reducing consumption of fructose found in many processed foods can significantly decrease liver fat.



Making these healthy habits a daily routine can lead to better liver health and overall wellness.


Diagnosis and Treatment


If you suspect fatty liver disease, or is at risk for fatty liver, your healthcare provider may suggest several diagnostic tests:


  • Blood Tests: These assess liver function and rule out other liver diseases.


  • Imaging Studies: Tools like ultrasounds, CT scans, and MRIs can effectively visualize fat in the liver.


  • Liver Biopsy: In some instances, a biopsy may be necessary to determine the extent of liver damage.


Most treatment plans revolve around lifestyle modifications, with dietary changes and increased physical activity being key. In more severe cases, doctors may prescribe medications to manage related health issues like diabetes or high cholesterol.


Living with Fatty Liver Disease


For those diagnosed with fatty liver disease, managing the condition is crucial to prevent further complications. Regular follow-ups with healthcare providers, adherence to treatment plans, and a strong commitment to healthy living can make a substantial difference.


Education is vital. Understanding the disease, potential complications, and management strategies empowers patients and their families. Joining support groups or seeking counseling can provide additional resources and encouragement.


Taking Action


Fatty liver disease is a silent epidemic that requires both awareness and proactive management. Increasing knowledge, implementing healthy lifestyle changes, and scheduling regular health check-ups are essential in combating this prevalent condition.


By making informed choices today, you can protect your liver and enhance your overall well-being. Stay informed, stay active, and make your liver health a priority.


Our preventionplus app is specifically designed to track and reverse lifestyle related chronic illnesses-to learn more about this and to sign up, go to https://www.preventiononly.com/theapp


References

  1. The Global Epidemiology of Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH): A Systematic Review. Younossi ZM, Golabi P, Paik JM, et al. Hepatology (Baltimore, Md.). 2023;77(4):1335-1347. doi:10.1097/HEP.0000000000000004.

  2. Global burden of NAFLD 1990–2021 and projections to 2035: Results from the Global Burden of Disease study 2021. Mao Y, Du J, Li B, et al. PloS One. 2025;20(8):e0330504. doi:10.1371/journal.pone.0330504.

  3. Advancing the global public health agenda for NAFLD: a consensus statement. Lazarus JV, Mark HE, Anstee QM, et al. Nature Reviews. Gastroenterology & Hepatology. 2022;19(1):60-78. doi:10.1038/s41575-021-00523-4.

  4. Nonalcoholic Steatohepatitis. Sheka AC, Adeyi O, Thompson J, et al. JAMA. 2020;323(12):1175-1183. doi:10.1001/jama.2020.2298.

  5. Significant burden of nonalcoholic fatty liver disease with advanced fibrosis in the US: a cross‐sectional analysis of 2011‐2014 National Health and Nutrition Examination Survey. Wong RJ, Liu B, Bhuket T. Alimentary Pharmacology & Therapeutics. 2017;46(10):974-980. doi:10.1111/apt.14327.

  6. AASLD Practice Guidance on the Clinical Assessment and Management of Nonalcoholic Fatty Liver Disease. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. Hepatology (Baltimore, Md.). 2023;77(5):1797-1835. doi:10.1097/HEP.0000000000000323.

  7. AGA Clinical Practice Update: Diagnosis and Management Of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review. Long MT, Noureddin M, Lim JK. Gastroenterology. 2022;163(3):764-774.e1. doi:10.1053/j.gastro.2022.06.023.

  8. Emerging role of genomic analysis in clinical evaluation of lean individuals with NAFLD. Vilarinho S, Ajmera V, Zheng M, Loomba R. Hepatology (Baltimore, Md.). 2021;74(4):2241-2250. doi:10.1002/hep.32047.

  9. Non-Alcoholic Fatty Liver Disease. Powell EE, Wong VW, Rinella M. Lancet (London, England). 2021;397(10290):2212-2224. doi:10.1016/S0140-6736(20)32511-3.

  10. Incidence of liver‐related morbidity and mortality in a population cohort of non‐alcoholic fatty liver disease. Männistö VT, Salomaa V, Färkkilä M, et al. Liver International : Official Journal of the International Association for the Study of the Liver. 2021;41(11):2590-2600. doi:10.1111/liv.15004.

  11. The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients With Type 2 Diabetes. Younossi ZM, Golabi P, Price JK, et al. Clinical Gastroenterology and Hepatology : The Official Clinical Practice Journal of the American Gastroenterological Association. 2024;22(10):1999-2010.e8. doi:10.1016/j.cgh.2024.03.006.

  12. Global Prevalence of Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes Mellitus: An Updated Systematic Review and Meta-Analysis. En Li Cho E, Ang CZ, Quek J, et al. Gut. 2023;72(11):2138-2148. doi:10.1136/gutjnl-2023-330110.

  13. Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association. Duell PB, Welty FK, Miller M, et al. Arteriosclerosis, Thrombosis, and Vascular Biology. 2022;42(6):e168-e185. doi:10.1161/ATV.0000000000000153.

  14. AGA Clinical Practice Update on Lifestyle Modification Using Diet and Exercise to Achieve Weight Loss in the Management of Nonalcoholic Fatty Liver Disease: Expert Review. Younossi ZM, Corey KE, Lim JK. Gastroenterology. 2021;160(3):912-918. doi:10.1053/j.gastro.2020.11.051.

  15. Global, regional, and national burden of NAFLD in adults aged 20–49 years (1990–2021): a comprehensive analysis of trends, decomposition, and health inequality. Zhong Z, Xu M, Luo X, Tan J. BMC Gastroenterology. 2025;26(1):23. doi:10.1186/s12876-025-04497-4.

  16. Review article: the epidemiologic burden of non‐alcoholic fatty liver disease across the world. Henry L, Paik J, Younossi ZM. Alimentary Pharmacology & Therapeutics. 2022;56(6):942-956. doi:10.1111/apt.17158.

  17. Liver‐related and extrahepatic events in patients with non‐alcoholic fatty liver disease: a retrospective competing risks analysis. Pennisi G, Enea M, Romero-Gomez M, et al. Alimentary Pharmacology & Therapeutics. 2022;55(5):604-615. doi:10.1111/apt.16763.

  18. High Prevalence of Metabolic Dysfunction–Associated Steatohepatitis With Significant Fibrosis in Primary Care and Endocrinology Clinics. Kalavalapalli S, Leiva EG, Rocha AO, et al. Diabetes, Obesity & Metabolism. 2026;28(7):6184-6193. doi:10.1111/dom.70799.

Comments

bottom of page